Linked Life Data

20954333

Source:http://linkedlifedata.com/resource/pubmed/id/20954333

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2010-10-18
pubmed:abstractText
Recent molecular biological analyses of leukemia cells have revealed that deregulation of various cellular signaling pathways and deregulation of epigenetic regulation are involved in the development of leukemia. Based on these findings, many kinds of small molecular compounds have been developed to inhibit the function of proteins that are involved in signaling pathways or to modify the epigenetic regulation. These reagents include tyrosine kinase inhibitors, histone deacetylase inhibitors and DNA metyltransferase inhibitors. Furthermore, a monoclonal antibody against CD33 conjugated to an anti-cancer agent is currently being used for AML treatment. Effects of combinations of these reagents have also been examined in detail. These molecular targeted therapies are expected to improve the effectiveness of leukemia therapy.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0047-1852
pubmed:author
pubmed:issnType
Print
pubmed:volume
68
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1876-80
pubmed:dateRevised
2011-7-27
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Molecular targeted therapeutics for leukemia].
pubmed:affiliation
Division of Hematology, Department of Medicine, Jichi Medical University.
pubmed:publicationType
Journal Article, English Abstract, Review